Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer.

A Xu-VuillardC Guerin-CharbonnelF BocquetS CheesemanP M KubelacM ZenatriG HallP Achimas-CadariuB HanvicH FentonA-M-L Sturz-LazărP AugereauI R CoquardA LearyJ-S Frenel

Published in: ESMO open (2024)

This is the largest real-world study assessing the efficacy of subsequent chemotherapy in patients progressing during PARPi exposure. The patients have poor outcomes. PBC is the best option in patients progressing on PARPi and eligible for PBC rechallenge (PFI >6 months).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
type diabetes
patient reported outcomes
radiation therapy
metabolic syndrome